About Gilead Sciences
At Gilead, we have pioneered more than 25 products since our founding in 1987 and have an expanding portfolio of investigational medicines.
We have helped transform care for people living with HIV, developing the world’s first HIV single-tablet regimen to treat the disease and the first medicines to prevent infection with the HIV virus. Our scientists are continuing to pursue new kinds of treatment, such as long-acting antivirals, and the ultimate goal: a cure. Building on our success in HIV, we applied the same tenacity to hepatitis C virus (HCV), delivering four curative treatments in less than four years.
Gilead recognizes that improving public health requires more than just medicine. Through our partnerships with community organizations, we work to help improve access to care, reduce disparities, improve education and support local communities.
Gilead’s corporate giving programs fund projects that support underserved communities, which systematically experience social or economic obstacles to health. Our goal is to partner with patients and communities to build collaborative solutions that help extend access to care as broadly as possible. We build relationships with patient advocates, nonprofits and healthcare professionals around the world who work tirelessly in local communities to improve people’s lives.
In 2020, Gilead provided $409 million in cash donations to reduce health disparities, eliminate the barriers to healthcare encountered by underserved populations, advance education among healthcare professionals and support the local communities in which we operate.
Global Reach and Impact
Millions of people around the world are living healthier lives because of innovative medicines developed by Gilead.
Recognized as the top corporate philanthropic HIV donor by Funders Concerned About AIDS for five consecutive years.
Number of employees in offices across six continents.